JP2011526295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526295A5 JP2011526295A5 JP2011516650A JP2011516650A JP2011526295A5 JP 2011526295 A5 JP2011526295 A5 JP 2011526295A5 JP 2011516650 A JP2011516650 A JP 2011516650A JP 2011516650 A JP2011516650 A JP 2011516650A JP 2011526295 A5 JP2011526295 A5 JP 2011526295A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- alkyl
- hydrogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 127
- -1 nitro, benzimidazolyl Chemical group 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
- 150000002431 hydrogen Chemical class 0.000 claims description 26
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 23
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000006413 ring segment Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000005605 benzo group Chemical group 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 230000000698 schizophrenic effect Effects 0.000 claims description 3
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 230000003274 myotonic effect Effects 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 206010034158 Pathological gambling Diseases 0.000 claims 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 14
- 125000000000 cycloalkoxy group Chemical group 0.000 description 10
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 125000004663 dialkyl amino group Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004001 thioalkyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- KPUFNLPDWGSMGZ-UHFFFAOYSA-N carboxy(nitro)azanide Chemical group OC(=O)[N-][N+]([O-])=O KPUFNLPDWGSMGZ-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7559408P | 2008-06-25 | 2008-06-25 | |
| US61/075,594 | 2008-06-25 | ||
| US10916208P | 2008-10-28 | 2008-10-28 | |
| US61/109,162 | 2008-10-28 | ||
| US13886608P | 2008-12-18 | 2008-12-18 | |
| US61/138,866 | 2008-12-18 | ||
| US17641309P | 2009-05-07 | 2009-05-07 | |
| US61/176,413 | 2009-05-07 | ||
| PCT/US2009/048617 WO2009158473A1 (en) | 2008-06-25 | 2009-06-25 | 5- and 6-membered heterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526295A JP2011526295A (ja) | 2011-10-06 |
| JP2011526295A5 true JP2011526295A5 (enExample) | 2012-08-09 |
Family
ID=41119866
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516574A Expired - Fee Related JP5658664B2 (ja) | 2008-06-25 | 2009-06-24 | １，２−二置換複素環式化合物 |
| JP2011516650A Pending JP2011526295A (ja) | 2008-06-25 | 2009-06-25 | ５員および６員複素環化合物 |
| JP2014241945A Expired - Fee Related JP5820921B2 (ja) | 2008-06-25 | 2014-11-28 | １，２−二置換複素環式化合物 |
| JP2015197316A Pending JP2016014061A (ja) | 2008-06-25 | 2015-10-05 | １，２−二置換複素環式化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516574A Expired - Fee Related JP5658664B2 (ja) | 2008-06-25 | 2009-06-24 | １，２−二置換複素環式化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014241945A Expired - Fee Related JP5820921B2 (ja) | 2008-06-25 | 2014-11-28 | １，２−二置換複素環式化合物 |
| JP2015197316A Pending JP2016014061A (ja) | 2008-06-25 | 2015-10-05 | １，２−二置換複素環式化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US8071595B2 (enExample) |
| EP (2) | EP2297133B1 (enExample) |
| JP (4) | JP5658664B2 (enExample) |
| KR (2) | KR20110031355A (enExample) |
| CN (2) | CN102131801B (enExample) |
| AU (2) | AU2009262241B2 (enExample) |
| BR (2) | BRPI0914772A2 (enExample) |
| CA (2) | CA2729259A1 (enExample) |
| MX (2) | MX2011000175A (enExample) |
| TW (2) | TWI458723B (enExample) |
| WO (2) | WO2009158393A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| MX2011000175A (es) | 2008-06-25 | 2011-06-27 | Envivo Pharmaceuticals Inc | Compuestos heterociclicos 1,2-di-substituidos. |
| DK2617420T3 (da) | 2009-05-07 | 2015-12-07 | Forum Pharmaceuticals Inc | Heterocykliske phenoxymethylforbindelser |
| WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| JP5760085B2 (ja) * | 2010-08-04 | 2015-08-05 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| EP2602255B1 (en) | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| PL2619208T3 (pl) | 2010-09-20 | 2017-03-31 | Ironwood Pharmaceuticals, Inc. | Związki imidazotriazynonu |
| US8765760B2 (en) | 2011-01-11 | 2014-07-01 | Sunovion Pharmaceuticals, Inc. | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases |
| SG192839A1 (en) | 2011-02-18 | 2013-09-30 | Allergan Inc | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
| WO2013047411A1 (ja) * | 2011-09-29 | 2013-04-04 | 富士フイルム株式会社 | 新規なトリアジン誘導体、紫外線吸収剤 |
| WO2013142269A1 (en) * | 2012-03-19 | 2013-09-26 | Envivo Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| WO2013185284A1 (en) | 2012-06-12 | 2013-12-19 | Abbott Laboratories | Pyridinone and pyridazinone derivatives |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
| EP2975037A4 (en) | 2013-03-15 | 2016-08-10 | Daiichi Sankyo Co Ltd | benzothiophene derivative |
| TWI634114B (zh) * | 2013-05-08 | 2018-09-01 | 永恒生物科技公司 | 作為激酶抑制劑之呋喃酮化合物 |
| AU2014300673B2 (en) | 2013-06-27 | 2017-12-14 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| CN104211638A (zh) * | 2014-08-13 | 2014-12-17 | 李增 | 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用 |
| CN104610134B (zh) * | 2015-01-29 | 2017-01-25 | 安徽星宇化工有限公司 | 一种6‑甲基‑2‑吡啶基甲醇的制备方法 |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| BR112018067964B1 (pt) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc | Composto, composição farmacêutica que o compreende e uso do referido composto |
| JP2020512400A (ja) * | 2017-03-23 | 2020-04-23 | クラヴィウス ファーマシューティカルズ，エルエルシー | ＴＧＦβの阻害のための三置換イミダゾールおよび治療方法 |
| EP3612522A4 (en) * | 2017-04-18 | 2021-07-07 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| TWI811236B (zh) | 2017-08-28 | 2023-08-11 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| JP7147048B2 (ja) | 2018-08-22 | 2022-10-04 | クラヴィウス ファーマシューティカルズ，エルエルシー | Ｔｇｆ－ベータを阻害するための置換イミダゾールおよび処置方法 |
| CA3113235A1 (en) | 2018-09-21 | 2020-03-26 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| KR102811543B1 (ko) | 2019-10-16 | 2025-05-23 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 다환 화합물 |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| WO2023059224A1 (en) | 2021-10-09 | 2023-04-13 | Joint Stock Company "Pharmasyntez" | A new class of antiviral drugs |
| AU2023406476A1 (en) | 2022-12-02 | 2025-06-05 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002010158A2 (en) * | 2000-07-27 | 2002-02-07 | F. Hoffmann-La Roche Ag | 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| CA2493854A1 (en) | 2002-06-26 | 2004-01-08 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
| CN101098866A (zh) * | 2005-01-07 | 2008-01-02 | 辉瑞产品公司 | 杂芳族喹啉化合物及其作为pde10抑制剂的用途 |
| JP2007145819A (ja) * | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
| US20090176829A1 (en) * | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
| WO2008033455A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
| RU2439062C2 (ru) * | 2006-10-19 | 2012-01-10 | Ф.Хоффманн-Ля Рош Аг | Производные имидазолона и имидазолидинона как 11в-hsd1 ингибиторы при диабете |
| FR2928924B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| MX2011000175A (es) | 2008-06-25 | 2011-06-27 | Envivo Pharmaceuticals Inc | Compuestos heterociclicos 1,2-di-substituidos. |
| DK2617420T3 (da) * | 2009-05-07 | 2015-12-07 | Forum Pharmaceuticals Inc | Heterocykliske phenoxymethylforbindelser |
| RU2012109233A (ru) * | 2009-09-03 | 2013-10-10 | Аллерган, Инк. | Соединения как модуляторы тирозинкиназы |
| CN104672202B (zh) * | 2010-08-18 | 2017-07-28 | 萨穆梅德有限公司 | 作为联蛋白信号通路激活剂的二酮与羟基酮 |
-
2009
- 2009-06-24 MX MX2011000175A patent/MX2011000175A/es active IP Right Grant
- 2009-06-24 JP JP2011516574A patent/JP5658664B2/ja not_active Expired - Fee Related
- 2009-06-24 AU AU2009262241A patent/AU2009262241B2/en not_active Ceased
- 2009-06-24 KR KR1020117001942A patent/KR20110031355A/ko not_active Abandoned
- 2009-06-24 CA CA2729259A patent/CA2729259A1/en not_active Abandoned
- 2009-06-24 US US12/490,808 patent/US8071595B2/en not_active Expired - Fee Related
- 2009-06-24 CN CN200980133288.7A patent/CN102131801B/zh not_active Expired - Fee Related
- 2009-06-24 BR BRPI0914772A patent/BRPI0914772A2/pt not_active IP Right Cessation
- 2009-06-24 WO PCT/US2009/048426 patent/WO2009158393A1/en not_active Ceased
- 2009-06-24 EP EP09770926.5A patent/EP2297133B1/en active Active
- 2009-06-25 AU AU2009262156A patent/AU2009262156A1/en not_active Abandoned
- 2009-06-25 TW TW098121521A patent/TWI458723B/zh not_active IP Right Cessation
- 2009-06-25 MX MX2011000176A patent/MX2011000176A/es not_active Application Discontinuation
- 2009-06-25 US US13/001,359 patent/US8481534B2/en not_active Expired - Fee Related
- 2009-06-25 KR KR1020117001893A patent/KR20110029153A/ko not_active Withdrawn
- 2009-06-25 CA CA2729275A patent/CA2729275A1/en not_active Abandoned
- 2009-06-25 BR BRPI0913958A patent/BRPI0913958A2/pt not_active IP Right Cessation
- 2009-06-25 CN CN2009801332730A patent/CN102131800A/zh active Pending
- 2009-06-25 TW TW103127120A patent/TWI542590B/zh not_active IP Right Cessation
- 2009-06-25 WO PCT/US2009/048617 patent/WO2009158473A1/en not_active Ceased
- 2009-06-25 JP JP2011516650A patent/JP2011526295A/ja active Pending
- 2009-06-25 EP EP09771005A patent/EP2303863A1/en not_active Withdrawn
-
2011
- 2011-11-07 US US13/290,527 patent/US8466148B2/en not_active Expired - Fee Related
-
2013
- 2013-06-17 US US13/919,320 patent/US8933074B2/en not_active Expired - Fee Related
- 2013-06-17 US US13/919,516 patent/US20140038965A1/en not_active Abandoned
-
2014
- 2014-10-31 US US14/529,435 patent/US9265767B2/en not_active Expired - Fee Related
- 2014-11-28 JP JP2014241945A patent/JP5820921B2/ja not_active Expired - Fee Related
- 2014-12-19 US US14/576,550 patent/US20150344467A1/en not_active Abandoned
-
2015
- 2015-10-05 JP JP2015197316A patent/JP2016014061A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526295A5 (enExample) | ||
| JP2011526294A5 (enExample) | ||
| JP2011526282A5 (enExample) | ||
| JP6059342B2 (ja) | ｃ−ＭＥＴチロシンキナーゼ阻害剤として有用な新規な縮合ピリジン誘導体 | |
| CA2666563C (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| CN101848895B (zh) | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 | |
| EP4469449A1 (en) | Parp1 inhibitors and uses thereof | |
| BR112015006686B1 (pt) | Combinação de regorafenib e ácido acetilsalicílico para tratamento de câncer coloretal | |
| JP2014517017A5 (ja) | 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用 | |
| JP2014521625A5 (enExample) | ||
| JP2013545823A5 (enExample) | ||
| JP2025518592A (ja) | 二環式誘導体ｐａｒｐ阻害剤及びその用途 | |
| JP2012526107A5 (enExample) | ||
| KR20120075481A (ko) | 치료적 유용성을 갖는 수용체 조절제로서 쿠마린 화합물 | |
| CA2642835C (en) | Salt of sulfinylbenzimidazole compound, and crystal and amorphous form thereof | |
| JP2003513066A5 (enExample) | ||
| RU2002114041A (ru) | N-гуанидиноалкиламиды, их получение, их применение и содержащие их фармацевтические препараты | |
| TWI853869B (zh) | 戊烷脒之類似物及其用途 | |
| CN106117182B (zh) | 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用 | |
| CN110156782B (zh) | 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物 | |
| CN105777808A (zh) | 替唑尼特磷酸酯和烷基磺酸酯及其在药学中的应用 | |
| JP2019526593A5 (enExample) | ||
| EP2624833A1 (en) | 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer | |
| CN106045973A (zh) | 4‑酰胺基苯并咪唑吖啶类化合物及其制备方法和用途 | |
| CN102850364B (zh) | 鬼臼衍生物及其组合物、制备方法和应用 |